Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515545 | 0.94 | NR1H3 (0.44) | NR1H3HRH3SLC6A4OPRK1KCNH2 | |
| SCHEMBL6515170 | 0.93 | NR1H3 (0.44) | NR1H3HRH3SLC6A4OPRK1KCNH2 | |
| SCHEMBL6519456 | 0.92 | NR1H3 (0.43) | NR1H3HRH3SLC6A4KCNH2OPRM1 | |
| SCHEMBL6564859 | 0.90 | NR1H3 (0.42) | NR1H3HRH3SLC6A4MEN1KMT2A | |
| SCHEMBL6515354 | 0.89 | NR1H3 (0.54) | NR1H3OPRK1KCNH2OPRM1ESR1 | |
| SCHEMBL6510586 | 0.89 | NR1H3 (0.48) | NR1H3HRH3SLC6A4MEN1KMT2A | |
| SCHEMBL6519566 | 0.89 | NR1H3 (0.42) | NR1H3OPRK1OPRM1OPRD1ALDH1A1 | |
| SCHEMBL6515253 | 0.88 | OPRK1 (0.51) | NR1H3OPRK1KCNH2OPRM1OPRD1 | |
| SCHEMBL6567185 | 0.84 | NR1H3 (0.43) | NR1H3HRH3SLC6A4OPRK1KCNH2 | |
| SCHEMBL6515535 | 0.84 | NR1H3 (0.46) | NR1H3MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318976-B1 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LTD (GB) | 2004-11-24 | — | — | EP | claimed |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| JP-2004509161-A | — | — | 2004-03-25 | — | — | JP | claimed |
| EP-1318976-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024632-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | claimed |
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | disclosed |
| EP-1318976-B1 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LTD (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1318976-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024632-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885HRH3 2306/4885SLC6A4 2582/4885 |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | NR1H2, NR1H3, NR1H4 | NR1H3 2/4885HRH3 2126/4885SLC6A4 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.